Mycoplasmas including CBPP/CCPP roadmap:
Vaccines
Research roadmap for contagious bovine pleuropneumonia (CBPP) vaccine development
Download CBPP vaccine development roadmap final4
Inactivated vaccines
Inactivated vaccines
Research Question
- A bacterin vaccine should be intrinsically safer than T1/44 and bypasses the need to identify antigens associated with immunity.
Attempts to develop an efficacious bacterin has not so far been successful.
Research Gaps and Challenges
- It is not clear why Mmm bacterins have failed as the vaccine for CCPP is based on a bacterin.
Could be due to antigenic differences between in vitro cultured Mmm and Mmm during an infection.
Sub-optimal adjuvants and antigen doses were tested in previous studies. - Lack of in vitro assays that correlate/associate with immunity to CBPP.
Solution Routes
- More comprehensive proteomic comparison of in vitro versus in vivo Mmm.
- Testing of new generation adjuvants may provide better immunostimulatory signals.
- Increase quality and quantity of immune response in the lungs.
Dependencies
- Standardized cattle breed specific laboratory challenge models that reproduce CBPP caused by natural infection or are acceptable surrogate models.
- Knowledge on the Mmm targets of host immune responses that contribute to disease and immunity.
State Of the Art
- Aluminium hydroxide used in a bacterin with no success.
- Montanide gave limited efficacy.
Projects
What activities are planned or underway?
Collaborative project: Stressless examination for pathogens associated with bovine respiratory disease complex Stressless fUtuRE – subproject B (SURE)
Planned Completion date 31/05/2024
Source Countries:
Denmark
Collaborative project: Stressless examination for pathogens associated with bovine respiratory disease complex Stressless fUtuRE – subproject A (SURE)
Planned Completion date 31/05/2024
Source Countries:
Denmark